Mirati Therapeutics Inc.’s update on the phase I/II Krystal trial of the KRAS-G12C-targeting adagrasib (MRTX-849) was arguably the most eagerly awaited news, and certainly the most eagerly awaited KRAS-targeting news, to come out of the 2020 EORTC-NCI-AACR (ENA) Molecular Targets meeting. KRAS is one of the most frequently mutated oncogenes across a wide swath of solid tumors, and has been one of the toughest nuts to crack as far as druggability is concerned.
A multi-institutional team of researchers has implicated lipid droplets, which are key energy storage units of individual cells, in innate immune defense. "Until now it was thought that [lipid droplets] were at the service of viruses or bacteria during infection," Albert Pol told BioWorld. The new study, which was published in the Oct. 16, 2020, issue of Science, demonstrated that cells also use the droplets to coordinate their defense.
Keeping you up to date on recent developments in oncology, including: Study supports use of hypofractionated SRT to resection cavity in brain metastases; PDAC subtypes point to targeting strategies; NICE endorses Tagrisso; Nanofibers show well in study of skin cancer.
Keeping you up to date on recent developments in cardiology, including: Biobeat's wearable monitoring device shows promise in swine model; Neutrophils are literal obstacle to stroke recovery; Neovessel formation eyed in treating cardiovascular diseases.
A multi-institutional team of researchers has implicated lipid droplets, which are key energy storage units of individual cells, in innate immune defense.
Keeping you up to date on recent developments in neurology, including: Study highlights links between inflammation and Parkinson’s disease; Some sedentariness in older adults OK when it comes to brain, cognition; Microbiome metabolite affects neuropathic pain; Following neonatal lead enables spinal cord repair in mice.
Investigators at the ECOG-ACRIN Cancer Research Group and the National Cancer Institute reported a roughly 40% match rate of patients to molecularly targeted therapies in its NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial, ultimately leading to molecularly targeted treatments for almost 20% of trial participants.
